Jonathan Moss to Narcotic Antagonists
This is a "connection" page, showing publications Jonathan Moss has written about Narcotic Antagonists.
Connection Strength
2.312
-
Identifying and Treating Opioid Side Effects: The Development of Methylnaltrexone. Anesthesiology. 2019 01; 130(1):142-148.
Score: 0.578
-
Methylnaltrexone (Relistor®) does not impact opioid-mediated analgesia at therapeutic doses. Pain. 2014 Dec; 155(12):2722.
Score: 0.427
-
Subcutaneous methylnaltrexone to restore postoperative bowel function in a long-term opiate user. Int J Gynecol Cancer. 2010 Feb; 20(2):308-10.
Score: 0.312
-
Reversal of opioid-induced gastric dysfunction in a critically ill burn patient after methylnaltrexone. Anesth Analg. 2008 Dec; 107(6):1965-7.
Score: 0.287
-
Development of peripheral opioid antagonists' new insights into opioid effects. Mayo Clin Proc. 2008 Oct; 83(10):1116-30.
Score: 0.284
-
Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005 May; 45(5):538-46.
Score: 0.224
-
The mu opioid receptor: A new target for cancer therapy? Cancer. 2015 Aug 15; 121(16):2681-8.
Score: 0.113
-
Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol. 2007 Aug; 37(2):222-31.
Score: 0.064
-
The µ-opioid receptor in cancer progression: is there a direct effect? Anesthesiology. 2012 Apr; 116(4):940-5.
Score: 0.023